8 results about "Human cancer" patented technology

The application relates to the technical field of pharmaceutical chemistry, and discloses a sulfuryl hydrazone compound, a preparation method thereof and anti-tumor application. The compound is synthesized from isatin derivatives and sulfuryl hydrazine through two-step nucleophilic substitution-elimination reaction, has a chemical structure as shown in formula (I), and is characterized by 1H NMR, 13C NMR and HRMS. The sulfuryl hydrazone compound has significant inhibitory activity on A549 (lung cancer), HepG2 (liver cancer) and Hela (cervical cancer) three human cancer cell strains, the value of some compounds is as low as 0.03 micromole / L, the compound can induce cell apoptosis by mediating ROS generation in tumor cells, inhibiting the NF-kappa B signal pathway and activating Caspase-3 activity, and can effectively inhibit cancer cell migration and colony formation. The compound has a mild synthesis process, simple operation and wide substrate applicability, can be used as a potential anti-tumor active ingredient, can be used for preparing drugs for resisting lung cancer, liver cancer, cervical cancer and other tumors, and can provide new candidate compounds and technical support for cancer treatment.

Compositions and methods for analyzing repetitive sequences in the genome are provided, which are used in methods for large scale analysis of these regions for characterization, detection, and monitoring of human cancer.

The present application belongs to the field of polypeptides, and relates to a polypeptide with anti-tumor activity and application thereof, in particular to application thereof in preparation of a medicine for preventing and / or treating cancer. The amino acid sequence of the polypeptide of the present application is shown in SEQ ID NO: 1 or SEQ ID NO: 2. The cancer is at least one of breast cancer, cervical cancer, ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma and brain glioma. The present application has the following technical effects: the polypeptide targeting the FANCI-FANCD2 complex of Fanconi anemia complementation group I protein (FANCI) and Fanconi anemia complementation group D2 protein (FANCD2) is designed and synthesized, the polypeptide shows good inhibitory activity on various different types of human cancer cells, and is expected to be a candidate molecule of broad-spectrum anticancer drugs. The synthesis process of the polypeptide is relatively simple, and the polypeptide is convenient for large-scale preparation and has low production cost.

The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2 / interleukin-15 receptor βγ (IL-2 / IL-15Rβγ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2 / IL-15Rβγ agonists on 2, 3 or 4 consecutive days followed by days without administration.

Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.